Literature DB >> 1363256

On the relationship between the inhibition of thrombin stimulated aggregation and thromboxane formation in isolated platelets treated with beta-adrenoceptor blocking drugs.

R Nosál1, V Jancinová, M Petríková.   

Abstract

Thromboxane B2 (TXB2) formation in isolated, thrombin-stimulated rat platelets was time dependent and appeared after 5 s of incubation. Beta-adrenoceptor blocking (BAB) drugs inhibited thrombin-stimulated TXB2 formation in the following rank order of potency: metipranolol approximately alprenolol approximately propranolol > oxprenolol > practolol. Atenolol was ineffective in inhibiting TXB2 production in stimulated platelets. The inhibition of thrombin-stimulated TXB2 formation by BAB drugs correlated with their inhibitory effect on thrombin-stimulated platelet aggregation, arachidonic acid liberation from membrane phospholipids and with their membrane fluidization. The higher was the liposolubility of the beta-adrenoceptor blocking drugs investigated, the higher was their inhibition of stimulated TXB2 formation. Hydrophilic, selective atenolol and practolol revealed slight or no inhibitory effect on stimulated thromboxane production.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363256     DOI: 10.1016/0049-3848(92)90092-o

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  The H1-histamine antagonist Dithiaden inhibits human platelets in vitro.

Authors:  R Nosál; V Jancinová; E Danihelová
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

2.  The H1-histamine receptor antagonist dithiaden inhibits stimulated platelet aggregation, malondialdehyde formation and thromboxane production in vitro.

Authors:  R Nosál; V Jancinová; M Petríková
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

3.  Antihistaminic drug bromadryl and stimulated platelet aggregation.

Authors:  R Nosál; V Jancinová; M Petríková
Journal:  Agents Actions       Date:  1994-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.